Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Adding targeted radiation to chemotherapy prior to surgery may offer better control of pancreatic tumors—potentially reducing the rate of recurrence after treatment, according to a cohort study from Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login